Rahimi Nader
Rahimi Nader, MSc, PhD
Associate Professor and Director

Department of Pathology and Laboratory Medicine
Boston University


1987-1991 B.Sc Biochemistry University of Toronto
1992-1994 M.Sc Cell Biology Queen’s University, Kingston, Ont. Canada
1994-1996 PhD Cell Biology
Queen’s University, Kingston, Ont. Canada
1996-1999 Post.Doc Molecular Biology HarvardMedical School, Boston, MA



I have a broad expertise in cell signaling in particular in receptor tyrosine kinases, protein modification (phosphorylation, methylation, ubiquitination, acetylation and proteolytic cleavage modifications). We are also expert in various mouse and cell culture based angiogenesis and tumor models.

Research Interest

  • Cell Signaling In Particular In Receptor Tyrosine Kinases
  • Protein Modification (Phosphorylation, Methylation, Ubiquitination, Acetylation And Proteolytic Cleavage Modifications).
  • Mouse And Cell Culture Based Angiogenesis And Tumor Models.


Professional Activities:

2008 Associate Professor Department of Pathology Boston University
2008 Director of Graduate Studies Department of Pathology Boston University
 2011 Member Cancer Center Boston University
2005 Associate Professor Department of Ophthalmology Boston University
1999- 2005 Assistant Professor Department of Ophthalmology Boston University
1999 Assistant Professor Department of Biochemistry Boston University
1996-1999 Post-doctoral Research Associate Harvard Medical School Boston
1992-1996 Graduate Student Cancer Research Laboratories Queen’s University



  1. Huang Z, Marsiglia WM, Basu Roy U, Rahimi N, Ilghari D, Wang H, Chen H, Gai W, Blais S, Neubert TA, Mansukhani A, Traaseth NJ, Li X, Mohammadi M. Two FGF Receptor Kinase Molecules Act in Concert to Recruit and Transphosphorylate Phospholipase C?. Mol Cell. 2016 Jan 7; 61(1):98-110.
  2. Maghsoudlou A, Meyer RD, Rezazadeh K, Arafa E, Pudney J, Hartsough E, Rahimi N. RNF121 inhibits angiogenic growth factor signaling by restricting cell surface expression of VEGFR-2. Traffic. 2015 Nov 24.
  3. Arafa E, Bondzie PA, Rezazadeh K, Meyer RD, Hartsough E, Henderson JM, Schwartz JH, Chitalia V, Rahimi N. TMIGD1 Is a Novel Adhesion Molecule That Protects Epithelial Cells from Oxidative Cell Injury. Am J Pathol. 2015 Oct; 185(10):2757-67.
  4. Srinivasan S, Chitalia V, Meyer RD, Hartsough E, Mehta M, Harrold I, Anderson N, Feng H, Smith LE, Jiang Y, Costello CE, Rahimi N. Hypoxia-induced expression of phosducin-like 3 regulates expression of VEGFR-2 and promotes angiogenesis. Angiogenesis. 2015 Oct; 18(4):449-62.
  5. Shivanna S, Harrold I, Shashar M, Meyer R, Kiang C, Francis J, Zhao Q, Feng H, Edelman ER, Rahimi N, Chitalia VC. The c-Cbl Ubiquitin Ligase Regulates Nuclear ß-Catenin and Angiogenesis by Its Tyrosine Phosphorylation Mediated through the Wnt Signaling Pathway. J Biol Chem. 2015 May 15; 290(20):12537-46.
  6. Yu J, Rupasinghe C, Wilson JL, Taylor L, Rahimi N, Mierke D, Polgar P. Targeting receptor tyrosine kinases and their downstream signaling with cell-penetrating peptides in human pulmonary artery smooth muscle and endothelial cells. Chem Biol Drug Des. 2015 May; 85(5):586-97.
  7. Rahimi N, Costello CE. Emerging roles of post-translational modifications in signal transduction and angiogenesis. Proteomics. 2015 Jan; 15(2-3):300-9.
  8. Hartsough EJ, Meyer RD, Chitalia V, Jiang Y, Marquez VE, Zhdanova IV, Weinberg J, Costello CE, Rahimi N. Lysine methylation promotes VEGFR-2 activation and angiogenesis. Sci Signal. 2013 Dec 3; 6(304):ra104.
  9. Srinivasan S, Meyer RD, Lugo R, Rahimi N. Identification of PDCL3 as a novel chaperone protein involved in the generation of functional VEGF receptor 2. J Biol Chem. 2013 Aug 9; 288(32):23171-81.
  10. Chitalia V, Shivanna S, Martorell J, Meyer R, Edelman E, Rahimi N. c-Cbl, a ubiquitin E3 ligase that targets active ß-catenin: a novel layer of Wnt signaling regulation. J Biol Chem. 2013 Aug 9; 288(32):23505-17.
  11. Kilari S, Remadevi I, Zhao B, Pan J, Miao R, Ramchandran R, North PE, You M, Rahimi N, Wilkinson GA. Endothelial cell-specific chemotaxis receptor (ECSCR) enhances vascular endothelial growth factor (VEGF) receptor-2/kinase insert domain receptor (KDR) activation and promotes proteolysis of internalized KDR. J Biol Chem. 2013 Apr 12; 288(15):10265-74.
  12. Rahimi N, Rezazadeh K, Mahoney JE, Hartsough E, Meyer RD. Identification of IGPR-1 as a novel adhesion molecule involved in angiogenesis. Mol Biol Cell. 2012 May; 23(9):1646-56.
  13. Rahimi N. The ubiquitin-proteasome system meets angiogenesis. Mol Cancer Ther. 2012 Mar; 11(3):538-48.
  14. Meyer RD, Srinivasan S, Singh AJ, Mahoney JE, Gharahassanlou KR, Rahimi N. PEST motif serine and tyrosine phosphorylation controls vascular endothelial growth factor receptor 2 stability and downregulation. Mol Cell Biol. 2011 May; 31(10):2010-25.
  15. Boucher I, Kehasse A, Marcincin M, Rich C, Rahimi N, Trinkaus-Randall V. Distinct activation of epidermal growth factor receptor by UTP contributes to epithelial cell wound repair. Am J Pathol. 2011 Mar; 178(3):1092-105.
  16. Meyer RD, Husain D, Rahimi N. c-Cbl inhibits angiogenesis and tumor growth by suppressing activation of PLC?1. Oncogene. 2011 May 12; 30(19):2198-206.
  17. Husain D, Meyer RD, Mehta M, Pfeifer WM, Chou E, Navruzbekov G, Ahmed E, Rahimi N. Role of c-Cbl-dependent regulation of phospholipase Cgamma1 activation in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2010 Dec; 51(12):6803-9.
  18. Rahimi N. A role for protein ubiquitination in VEGFR-2 signalling and angiogenesis. Biochem Soc Trans. 2009 Dec; 37(Pt 6):1189-92.
  19. Rahimi N, Golde TE, Meyer RD. Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells. Cancer Res. 2009 Mar 15; 69(6):2607-14.
  20. Meyer RD, Sacks DB, Rahimi N. IQGAP1-dependent signaling pathway regulates endothelial cell proliferation and angiogenesis. PLoS One. 2008; 3(12):e3848.
  21. Singh AJ, Meyer RD, Navruzbekov G, Shelke R, Duan L, Band H, Leeman SE, Rahimi N. A critical role for the E3-ligase activity of c-Cbl in VEGFR-2-mediated PLCgamma1 activation and angiogenesis. Proc Natl Acad Sci U S A. 2007 Mar 27; 104(13):5413-8.
  22. Rahimi N. Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials. Exp Eye Res. 2006 Nov; 83(5):1005-16.
  23. Meyer RD, Qian X, Guo HC, Rahimi N. Leucine motif-dependent tyrosine autophosphorylation of type III receptor tyrosine kinases. J Biol Chem. 2006 Mar 31; 281(13):8620-7.
  24. Rahimi N. VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. Front Biosci. 2006; 11:818-29.
  25. Meyer RD, Mohammadi M, Rahimi N. A single amino acid substitution in the activation loop defines the decoy characteristic of VEGFR-1/FLT-1. J Biol Chem. 2006 Jan 13; 281(2):867-75.
  26. Singh AJ, Meyer RD, Band H, Rahimi N. The carboxyl terminus of VEGFR-2 is required for PKC-mediated down-regulation. Mol Biol Cell. 2005 Apr; 16(4):2106-18.
  27. Meyer RD, Singh A, Majnoun F, Latz C, Lashkari K, Rahimi N. Substitution of C-terminus of VEGFR-2 with VEGFR-1 promotes VEGFR-1 activation and endothelial cell proliferation. Oncogene. 2004 Jul 15; 23(32):5523-31.
  28. Holmqvist K, Cross MJ, Rolny C, Hägerkvist R, Rahimi N, Matsumoto T, Claesson-Welsh L, Welsh M. The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J Biol Chem. 2004 May 21; 279(21):22267-75.
  29. Chua CC, Rahimi N, Forsten-Williams K, Nugent MA. Heparan sulfate proteoglycans function as receptors for fibroblast growth factor-2 activation of extracellular signal-regulated kinases 1 and 2. Circ Res. 2004 Feb 20; 94(3):316-23.
  30. Meyer RD, Rahimi N. Comparative structure-function analysis of VEGFR-1 and VEGFR-2: What have we learned from chimeric systems? Ann N Y Acad Sci. 2003 May; 995:200-7.
  31. Meyer RD, Latz C, Rahimi N. Recruitment and activation of phospholipase Cgamma1 by vascular endothelial growth factor receptor-2 are required for tubulogenesis and differentiation of endothelial cells. J Biol Chem. 2003 May 2; 278(18):16347-55.
  32. Meyer RD, Dayanir V, Majnoun F, Rahimi N. The presence of a single tyrosine residue at the carboxyl domain of vascular endothelial growth factor receptor-2/FLK-1 regulates its autophosphorylation and activation of signaling molecules. J Biol Chem. 2002 Jul 26; 277(30):27081-7.
  33. Dayanir V, Meyer RD, Lashkari K, Rahimi N. Identification of tyrosine residues in vascular endothelial growth factor receptor-2/FLK-1 involved in activation of phosphatidylinositol 3-kinase and cell proliferation. J Biol Chem. 2001 May 25; 276(21):17686-92.
  34. Rahimi N, Dayanir V, Lashkari K. Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells. J Biol Chem. 2000 Jun 2; 275(22):16986-92.
  35. Lashkari K, Hirose T, Yazdany J, McMeel JW, Kazlauskas A, Rahimi N. Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol. 2000 Apr; 156(4):1337-44.
  36. Qiao H, Saulnier R, Patryzkat A, Rahimi N, Raptis L, Rossiter J, Tremblay E, Elliott B. Cooperative effect of hepatocyte growth factor and fibronectin in anchorage-independent survival of mammary carcinoma cells: requirement for phosphatidylinositol 3-kinase activity. Cell Growth Differ. 2000 Feb; 11(2):123-33.
  37. Rahimi N, Kazlauskas A. A role for cadherin-5 in regulation of vascular endothelial growth factor receptor 2 activity in endothelial cells. Mol Biol Cell. 1999 Oct; 10(10):3401-7.
  38. Lashkari K, Rahimi N, Kazlauskas A. Hepatocyte growth factor receptor in human RPE cells: implications in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1999 Jan; 40(1):149-56.
  39. Rahimi N, Hung W, Tremblay E, Saulnier R, Elliott B. c-Src kinase activity is required for hepatocyte growth factor-induced motility and anchorage-independent growth of mammary carcinoma cells. J Biol Chem. 1998 Dec 11; 273(50):33714-21.
  40. Rahimi N, Tremblay E, McAdam L, Roberts A, Elliott B. Autocrine secretion of TGF-beta 1 and TGF-beta 2 by pre-adipocytes and adipocytes: a potent negative regulator of adipocyte differentiation and proliferation of mammary carcinoma cells. In Vitro Cell Dev Biol Anim. 1998 May; 34(5):412-20.
  41. Rahimi N, Tremblay E, Elliott B. Phosphatidylinositol 3-kinase activity is required for hepatocyte growth factor-induced mitogenic signals in epithelial cells. J Biol Chem. 1996 Oct 4; 271(40):24850-5.
  42. Rahimi N, Etchells S, Elliott B. Hepatocyte growth factor (HGF) is a copper-binding protein: a facile probe for purification of HGF by immobilized Cu(II)-affinity chromatography. Protein Expr Purif. 1996 May; 7(3):329-33.
  43. Rahimi N, Tremblay E, McAdam L, Park M, Schwall R, Elliott B. Identification of a hepatocyte growth factor autocrine loop in a murine mammary carcinoma. Cell Growth Differ. 1996 Feb; 7(2):263-70.
  44. Saulnier R, Bhardwaj B, Klassen J, Leopold D, Rahimi N, Tremblay E, Mosher D, Elliott B. Fibronectin fibrils and growth factors stimulate anchorage-independent growth of a murine mammary carcinoma. Exp Cell Res. 1996 Feb 1; 222(2):360-9.
  45. Rahimi N, Saulnier R, Nakamura T, Park M, Elliott B. Role of hepatocyte growth factor in breast cancer: a novel mitogenic factor secreted by adipocytes. DNA Cell Biol. 1994 Dec; 13(12):1189-97.


clinical-laboratory-medicine-flyer Flyer